Plasminogen activator inhibitor-1 inhibitors: a patent review (2006 – present)

Bibliography

• Raghunath PN, Tomaszewski JE, Brady ST, Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995;15:1432-43
   PubMed Web of Science ®Google Scholar
• Stoop AA, Lupu F, Pannekoek H. Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: a potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes. Arterioscler Thromb Vasc Biol 2000;20:1143-9
   PubMed Web of Science ®Google Scholar
• Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996;16:539-45
   PubMed Web of Science ®Google Scholar
• Lupu F, Heim DA, Bachmann F, Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995;15:1444-55
   PubMed Web of Science ®Google Scholar
• Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 2000;15:290-301
   PubMed Web of Science ®Google Scholar
• Ma LJ, Fogo AB. PAI-1 and kidney fibrosis. Front Biosci 2009;14:2028-41
   Web of Science ®Google Scholar
• Andreasen PA. PAI-1 - a potential therapeutic target in cancer. Curr Drug Targets 2007;8:1030-41
   PubMed Web of Science ®Google Scholar
• Binder BR, Mihaly J. The plasminogen activator inhibitor "paradox" in cancer. Immunol Lett 2008;118:116-24
   PubMed Web of Science ®Google Scholar
• Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006;26:2200-7
   PubMed Web of Science ®Google Scholar
• Jankun J, Al-Senaidy A, Skrzypczak-Jankun E. Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review). Int J Mol Med 2012;29:3-11
   PubMed Web of Science ®Google Scholar
• Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 2012;157:291-8
   PubMed Web of Science ®Google Scholar
• Salomaa V, Stinson V, Kark JD, Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995;91:284-90
   PubMed Web of Science ®Google Scholar
• Booth NA, Robbie LA, Croll AM, Bennett B. Lysis of platelet-rich thrombi: the role of PAI-1. Ann NY Acad Sci 1992;667:70-80
   PubMed Web of Science ®Google Scholar
• Sherman PM, Lawrence DA, Yang AY, Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center. J Biol Chem 1992;267:7588-95
   PubMed Web of Science ®Google Scholar
• Eren M, Painter CA, Atkinson JB, Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 2002;106:491-6
   PubMed Web of Science ®Google Scholar
• Schafer K, Müller K, Hecke A, Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003;23:2097-103
   PubMed Web of Science ®Google Scholar
• Lijnen HR, Van Hoef B, Umans K, Collen D. Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1). J Thromb Haemost 2004;2:16-22
   PubMed Web of Science ®Google Scholar
• Lindahl TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989;62:748-51
   PubMed Web of Science ®Google Scholar
• Declerck PJ, De Mol M, Alessi MC, Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988;263:15454-61
   PubMed Web of Science ®Google Scholar
• Seiffert D, Ciambrone G, Wagner NV, The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem 1994;269:2659-66
   PubMed Web of Science ®Google Scholar
• Podor TJ, Campbell S, Chindemi P, Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma' fibrinogen. J Biol Chem 2002;277:7520-8
   PubMed Web of Science ®Google Scholar
• Wei Y, Eble JA, Wang Z, Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell 2001;12:2975-86
   PubMed Web of Science ®Google Scholar
• Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996;383:441-3
   PubMed Web of Science ®Google Scholar
• Kjøller L, Kanse SM, Kirkegaard T, Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997;232:420-9
   PubMed Web of Science ®Google Scholar
• Redmond EM, Cullen JP, Cahill PA, Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Circulation 2001;103:597-603
   PubMed Web of Science ®Google Scholar
• Isogai C, Laug WE, Shimada H, Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res 2001;61:5587-94
   PubMed Web of Science ®Google Scholar
• Palmieri D, Lee JW, Juliano RL, Church FC. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J Biol Chem 2002;277:40950-7
   PubMed Web of Science ®Google Scholar
• Chazaud B, Ricoux R, Christov C, Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 2002;160:237-46
   PubMed Web of Science ®Google Scholar
• Zhu Y, Farrehi PM, Fay WP. Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation 2001;103:3105-10
   PubMed Web of Science ®Google Scholar
• Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation 1999;99:2496-8
   PubMed Web of Science ®Google Scholar
• Elokdah H, Abou-Gharbia M, Hennan JK, Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem 2004;47:3491-4
   PubMed Web of Science ®Google Scholar
• Gorlatova NV, Cale JM, Elokdah H, Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. J Biol Chem 2007;282:9288-96
   PubMed Web of Science ®Google Scholar
• Chapman HA, Wei Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost 2001;86:124-9
   PubMed Web of Science ®Google Scholar
• Stefansson S, McMahon GA, Petitclerc E, Lawrence DA. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003;9:1545-64
   PubMed Web of Science ®Google Scholar
• Degryse B, Sier CF, Resnati M, PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Lett 2001;505:249-54
   PubMed Web of Science ®Google Scholar
• Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 2001;108:779-84
   PubMed Web of Science ®Google Scholar
• Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003;160:781-91
   PubMed Web of Science ®Google Scholar
• Li Y, Lu W, Bu G. Essential role of the low density lipoprotein receptor-related protein in vascular smooth muscle cell migration. FEBS Lett 2003;555:346-50
   PubMed Web of Science ®Google Scholar
• Degryse B, Neels JG, Czekay RP, The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004;279:22595-604
   PubMed Web of Science ®Google Scholar
• Gramling MW, Church FC. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res 2010;125:377-81
   PubMed Web of Science ®Google Scholar
• Ploplis VA. Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease. Curr Drug Targets 2011;12:1782-9
   PubMed Web of Science ®Google Scholar
• De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005;5:149-54
   PubMed Web of Science ®Google Scholar
• Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005;40:1215-20
   PubMed Web of Science ®Google Scholar
• Lopes C, Dina C, Durand E, Froguel P. PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia 2003;46:1284-90
   PubMed Web of Science ®Google Scholar
• Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63
   PubMed Web of Science ®Google Scholar
• Hamsten A, de Faire U, Walldius G, Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9
   PubMed Web of Science ®Google Scholar
• Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005;3:1879-83
   PubMed Web of Science ®Google Scholar
• Rott D, Leibowitz D, Finci-Yeheskel Z, The relationship of plasminogen activator inhibitor-1 levels to the ST deviation pattern of acute myocardial infarction. Cardiology 2009;112:56-9
   PubMed Web of Science ®Google Scholar
• Festa A, Williams K, Tracy RP, Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006;113:1753-9
   PubMed Web of Science ®Google Scholar
• Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007;18:240-5
   PubMed Web of Science ®Google Scholar
• Schneiderman J, Sawdey MS, Keeton MR, Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992;89:6998-7002
   PubMed Web of Science ®Google Scholar
• Lupu F, Bergonzelli GE, Heim DA, Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993;13:1090-100
   PubMed Web of Science ®Google Scholar
• Pandolfi A, Cetrullo D, Polishuck R, Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 2001;21:1378-82
   PubMed Web of Science ®Google Scholar
• Festa A, D'Agostino R Jr, Tracy RP, Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51:1131-7
   PubMed Web of Science ®Google Scholar
• Lee CC, Lorenzo C, Haffner SM, The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetologia 2013;56:112-20
   PubMed Web of Science ®Google Scholar
• Erzen B, Sabovic M. In young post-myocardial infarction male patients elevated plasminogen activator inhibitor-1 correlates with insulin resistance and endothelial dysfunction. Heart Vessels 2012
   PubMed Web of Science ®Google Scholar
• Mertens I, Verrijken A, Michiels JJ, Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006;30:1308-14
   PubMed Web of Science ®Google Scholar
• Eckel RH. Obesity. Circulation 2005;111:e257-9
   PubMed Web of Science ®Google Scholar
• Alessi MC, Bastelica D, Morange P, Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000;49:1374-80
   PubMed Web of Science ®Google Scholar
• Alessi MC, Peiretti F, Morange P, Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:860-7
   PubMed Web of Science ®Google Scholar
• Crandall DL, Groeling TM, Busler DE, Antrilli TM. Release of PAI-1 by human preadipocytes and adipocytes independent of insulin and IGF-1. Biochem Biophys Res Commun 2000;279:984-8
   PubMed Web of Science ®Google Scholar
• Venugopal J, Hanashiro K, Nagamine Y. Regulation of PAI-1 gene expression during adipogenesis. J Cell Biochem 2007;101:369-80
   PubMed Web of Science ®Google Scholar
• Belalcazar LM, Ballantyne CM, Lang W, Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol 2011;31:1689-95
   PubMed Web of Science ®Google Scholar
• Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004;28:1357-64
   PubMed Web of Science ®Google Scholar
• Ma LJ, Mao SL, Taylor KL, Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004;53:336-46
   PubMed Web of Science ®Google Scholar
• Jankun J, Skrzypczak-Jankun E. Yin and yang of the plasminogen activator inhibitor. Pol Arch Med Wewn 2009;119:410-17
   PubMed Web of Science ®Google Scholar
• Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006;17:2999-3012
   PubMed Web of Science ®Google Scholar
• Malgorzewicz S, Skrzypczak-Jankun E, Jankun J. Plasminogen activator inhibitor-1 in kidney pathology (Review). Int J Mol Med 2013;31:503-10
   PubMed Web of Science ®Google Scholar
• Choi JW, Lee JH, Park HS, Kim YS. PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma. J Clin Pathol 2011;64:893-7
   PubMed Web of Science ®Google Scholar
• Ohba K, Miyata Y, Kanda S, Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J Urol 2005;174:461-5
   PubMed Web of Science ®Google Scholar
• Zubac DP, Wentzel-Larsen T, Seidal T, Bostad L. Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy. BMC Urol 2010;10:20
   PubMed Web of Science ®Google Scholar
• Oda T, Miyao N, Takahashi A, Growth rates of primary and metastatic lesions of renal cell carcinoma. Int J Urol 2001;8(9):473-7
   PubMed Web of Science ®Google Scholar
• Matsuo S, López-Guisa JM, Cai X, Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 2005;67:2221-38
   PubMed Web of Science ®Google Scholar
• Montes R, Declerck PJ, Calvo A, Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1. Thromb Haemost 2000;84:65-70
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol 2012;227:493-507
   PubMed Web of Science ®Google Scholar
• Hattori N, Degen JL, Sisson TH, Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000;106:1341-50
   PubMed Web of Science ®Google Scholar
• Eitzman DT, McCoy RD, Zheng X, Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996;97:232-7
   PubMed Web of Science ®Google Scholar
• Senoo T, Hattori N, Tanimoto T, Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 2010;65:334-40
   PubMed Web of Science ®Google Scholar
• Huang WT, Vayalil PK, Miyata T, Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am J Respir Cell Mol Biol 2012;46:87-95
   PubMed Web of Science ®Google Scholar
• Wang H, Vohra BP, Zhang Y, Heuckeroth RO. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice. Hepatology 2005;42:1099-108
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Heuckeroth RO. PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett 2007;581:3098-104
   PubMed Web of Science ®Google Scholar
• Clouthier DE, Comerford SA, Hammer RE. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest 1997;100:2697-713
   PubMed Web of Science ®Google Scholar
• Hennan JK, Morgan GA, Swillo RE, Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost 2008;6:1558-64
   PubMed Web of Science ®Google Scholar
• Gardell SJ, Krueger JA, Antrilli TA, Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action. Mol Pharmacol 2007;72:897-906
   PubMed Web of Science ®Google Scholar
• Lucking AJ, Visvanathan A, Philippou H, Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis. J Thromb Haemost 2010;8:1333-9
   PubMed Web of Science ®Google Scholar
• Ye B, Chou YL, Karanjawala R, Synthesis and biological evaluation of piperazine-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1). Bioorg Med Chem Lett 2004;14:761-5
   PubMedGoogle Scholar
• Cale JM, Li SH, Warnock M, Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1. J Biol Chem 2010;285:7892-902
   PubMed Web of Science ®Google Scholar
• Skrzypczak-Jankun E, Jankun J. Theaflavin digallate inactivates plasminogen activator inhibitor: could tea help in Alzheimer's disease and obesity? Int J Mol Med 2010;26:45-50
   PubMed Web of Science ®Google Scholar
• Chen CH, Eng HL, Chang CJ, 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J Lab Clin Med 2003;142:100-5
   PubMed Web of Science ®Google Scholar
• El-Ayache NC, Li SH, Warnock M, Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1). Bioorg Med Chem Lett 2010;20:966-70
   PubMed Web of Science ®Google Scholar
• Izuhara Y, Takahashi S, Nangaku M, Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol 2008;28:672-7
   PubMed Web of Science ®Google Scholar
• Yamaoka N, Kawano Y, Izuhara Y, Structure-activity relationships of new 2-acylamino-3-thiophenecarboxylic acid dimers as plasminogen activator inhibitor-1 inhibitors. Chem Pharm Bull (Tokyo) 2010;58:615-19
   PubMed Web of Science ®Google Scholar
• Suzuki J, Ogawa M, Muto S, The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury. Expert Opin Ther Targets 2008;12:783-94
   PubMed Web of Science ®Google Scholar
• Suzuki J, Ogawa M, Muto S, A specific inhibitor of plasminogen activator inhibitor-1 suppresses rat autoimmune myocarditis. Expert Opin Ther Targets 2008;12:1313-20
   PubMed Web of Science ®Google Scholar
• Jain MR, Shetty S, Chakrabarti G, In vitro PAI-1 inhibitory activity of oxalamide derivatives. Eur J Med Chem 2008;43:880-4
   PubMed Web of Science ®Google Scholar
• Pandya V, Jain M, Chakrabarti G, Discovery of inhibitors of plasminogen activator inhibitor-1: structure-activity study of 5-nitro-2-phenoxybenzoic acid derivatives. Bioorg Med Chem Lett 2011;21:5701-6
   PubMedGoogle Scholar
• Ohtani A, Takagi T, Hirano A, Inhibitory effect of a new butadiene derivative on the production of plasminogen activator inhibitor-1 in cultured bovine endothelial cells. J Biochem 1996;120:1203-8
   PubMed Web of Science ®Google Scholar
• Miyazaki H, Ogiku T, Sai H, Design, synthesis, and evaluation of orally active inhibitors of plasminogen activator inhibitor-1 (PAI-1) production. Bioorg Med Chem Lett 2008;18:6419-22
   PubMed Web of Science ®Google Scholar
• Miyazaki H, Sai H, Ohmizu H, Synthesis and evaluation of 1,4-diphenylbutadiene derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) production. Bioorg Med Chem 2010;18:1968-79
   PubMed Web of Science ®Google Scholar
• Gils A, Declerck PJ. Plasminogen activator inhibitor-1. Curr Med Chem 2004;11:2323-34
   PubMed Web of Science ®Google Scholar
• Verhamme I, Kvassman JO, Day D, Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. J Biol Chem 1999;274:17511-17
   PubMed Web of Science ®Google Scholar
• Fossati A. Antiinflammatory effects of seaprose-S on various inflammation models. Drugs Exp Clin Res 1999;25:263-70
   PubMedGoogle Scholar
• Dan J, Belyea D, Gertner G, Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma. Arch Ophthalmol 2005;123:220-4
   PubMedGoogle Scholar
• Iwaki T, Tanaka A, Miyawaki Y, Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 2011;9:1200-6
   PubMed Web of Science ®Google Scholar
• Radha KS, Madhyastha HK, Nakajima Y, Emodin upregulates urokinase plasminogen activator, plasminogen activator inhibitor-1 and promotes wound healing in human fibroblasts. Vascul Pharmacol 2008;48:184-90
   PubMed Web of Science ®Google Scholar
• Bauman KA, Wettlaufer SH, Okunishi K, The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest 2010;120:1950-60
   PubMed Web of Science ®Google Scholar
• Yepes M, Sandkvist M, Wong MK, Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000;96:569-76
   PubMed Web of Science ®Google Scholar
• Armstead WM, Riley J, Kiessling JW, PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia. Am J Physiol Heart Circ Physiol 2010;299:H76-80
   Web of Science ®Google Scholar
• Krakovsky M, Polianski V, Nimrod A, THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models. Neurol Res 2011;33:983-90
   PubMed Web of Science ®Google Scholar
• Blake CM, Sullenger BA, Lawrence DA, Fortenberry YM. Antimetastatic potential of PAI-1-specific RNA aptamers. Oligonucleotides 2009;19:117-28
   PubMedGoogle Scholar
• Madsen JB, Dupont DM, Andersen TB, RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1. Biochemistry 2010;49:4103-15
   PubMed Web of Science ®Google Scholar
• Brandal S, Blake CM, Sullenger BA, Fortenberry YM. Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. Nucleic Acid Ther 2011;21:373-81
   PubMed Web of Science ®Google Scholar
• Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997;90:204-8
   PubMed Web of Science ®Google Scholar
• Iwaki T, Nagahashi K, Kobayashi T, The first report of uncontrollable subchorionic and retroplacental haemorrhage inducing preterm labour in complete PAI-1 deficiency in a human. Thromb Res 2012;129:e161-3
   Web of Science ®Google Scholar
• Rusconi CP, Scardino E, Layzer J, RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002;419:90-4
   PubMed Web of Science ®Google Scholar
• Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996;2:568-82
   PubMed Web of Science ®Google Scholar
• Serrano R, Barrenetxe J, Orbe J, Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats. Am J Physiol Regul Integr Comp Physiol 2009;297:R1563-9
   Web of Science ®Google Scholar